







Patient Name : PAYEL MONDAL : 25 Y 11 M 22 D Age

Gender : F Lab Add. : Newtown, Kolkata-700156

Ref Dr. : Dr.MEDICAL OFFICER

Collection Date : 26/Mar/2024 10:45AM : 26/Mar/2024 05:11PM Report Date

DEPARTMENT OF BIOCHEMISTRY

| Test Name | Result | Bio Ref. Interval | Unit |
|-----------|--------|-------------------|------|
| | | | |

PHOSPHORUS-INORGANIC,BLOOD, GEL 2.4-5.1 mg/dL mg/dL

SERUM (Method:Phosphomolybdate/UV)

*** End Of Report ***

MBBS MD (Biochemistry) Consultant Biochemist Reg No. WBMC 62456



: F

Patient Name : PAYEL MONDAL : 25 Y 11 M 22 D Age

Gender

Lab Add. : Nadia, Krishnanagar - 741101

: Dr.MEDICAL OFFICER

: 26/Mar/2024 01:22PM

Collection Date : 26/Mar/2024 10:45AM



DEPARTMENT OF BIOCHEMISTRY

Ref Dr.

Report Date

| Test Name | Result | Bio Ref. Interval | Unit |
|---|------------------|---|----------|
| GLUCOSE,PP (Method:Hexokinase Method) | 99 | Impaired Glucose Tolerance-140 to 199.~Diabetes>= 200. | mg/dL |
| SODIUM,BLOOD (Method:ISE DIRECT) | 141 | 136 - 145 | mEq/L |
| CHLORIDE,BLOOD (Method:ISE DIRECT) | 103 | 98 - 107 | mEq/L |
| CREATININE, BLOOD (Method:Jaffe, alkaline picrate, kinetic) | 0.67 | 0.5-1.1 | mg/dL |
| GLUCOSE,FASTING (Method:Hexokinase Method) | 90 | Impaired Fasting-100-125 .~Diabetes- >= 126.~Fasting is defined as no caloric intake for at least 8 hours. | mg/dL |
| CALCIUM,BLOOD (Method:Modified OCPC) | 9.20 | 8.7-10.4 mg/dL | mg/dL |
| URIC ACID,BLOOD (Method:URICASE) | 5.80 | 2.6-6.0 | mg/dL |
| *GLYCATED HAEMOGLOBIN (HBA1C), | EDTA WHOLE BLOOD | | |
| GLYCATED HEMOGLOBIN (HBA1C) | 4.5 | ***FOR BIOLOGICAL REFERENCE INTERVAL DETAILS , PLEASE REFER TO THE BELOW MENTIONED REMARKS/NOTE WITH ADDITIONAL CLINICAL INFORMATION *** | |
| HbA1c (IFCC) (Method:HPLC) | 26.0 | | mmol/mol |

Clinical Information and Laboratory clinical interpretation on Biological Reference Interval:

Low risk / Normal / non-diabetic : <5.7% (NGSP) / < 39 mmol/mol (IFCC) Pre-diabetes/High risk of Diabetes: 5.7%-6.4% (NGSP) / 39 - < 48 mmol/mol (IFCC) Diabetics-HbA1c level : >/= 6.5% (NGSP) / > 48 mmol/mol (IFCC)

Analyzer used :- Bio-Rad-D10 Method: HPLC Ion Exchange

Recommendations for glycemic targets

- Ø Patients should use self-monitoring of blood glucose (SMBG) and HbA1c levels to assess glycemic control.
- Ø The timing and frequency of SMBG should be tailored based on patients' individual treatment, needs, and goals.
- Ø Patients should undergo HbA1c testing at least twice a year if they are meeting treatment goals and have stable glycemic control.
- Ø If a patient changes treatment plans or does not meet his or her glycemic goals, HbA1c testing should be done quarterly.
- Ø For most adults who are not pregnant, HbA1c levels should be <7% to help reduce microvascular complications and macrovascular disease . Action suggested >8% as it indicates poor control.

Ø Some patients may benefit from HbA1c goals that are stringent.

Result alterations in the estimation has been established in many circumstances, such as after acute/ chronic blood loss, for example, after surgery, blood transfusions, hemolytic anemia, or high erythrocyte turnover; vitamin B₁₂/ folate deficiency, presence of chronic renal or liver disease; after administration of high-dose vitamin E / C; or erythropoietin treatment.

Reference: Glycated hemoglobin monitoring BMJ 2006; 333;586-8

- Chamberlain JJ, Rhinehart AS, Shaefer CF, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. Published online
- Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR, Miedema K, Myers GL, Reinauer H, Sacks DB, Weykamp CW. International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Scientific Division. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med. 2007;45(8):1077-1080.

Lab No. : KNK/26-03-2024/SR8911911

Page 2 of 12



Lab No. : KNK/26-03-2024/SR8911911 Lab Add. : Nadia, Krishnanagar - 741101

: PAYEL MONDAL Ref Dr. : Dr.MEDICAL OFFICER **Patient Name** : 25 Y 11 M 22 D **Collection Date** : 26/Mar/2024 10:45AM Age : 26/Mar/2024 01:22PM Gender : F Report Date



DEPARTMENT OF BIOCHEMISTRY

| Test Name Result Bio Ref. Interval Unit |
|---|
|---|

PDF Attached

| THYROID PANEL (T3, T4, TSH), GEL SERUM | | | | | |
|---|------|-----------------|--------|--|--|
| T3-TOTAL (TRI IODOTHYRONINE) (Method:CLIA) | 1.33 | 0.60-1.81 ng/ml | ng/ml | | |
| T4-TOTAL (THYROXINE) (Method:CLIA) | 11.4 | 3.2-12.6 | μg/dL | | |
| TSH (THYROID STIMULATING HORMONE) (Method:CLIA) | 1.27 | 0.35-5.5 | μlU/mL | | |

BIOLOGICAL REFERENCE INTERVAL: [ONLY FOR PREGNANT MOTHERS]

Trimester specific TSH LEVELS during pregnancy: FIRST TRIMESTER : 0.10 2.50 µ IU/mL SECOND TRIMESTER :0.20 3.00 µ IU/mL THIRD TRIMESTER :0.30 3.00 µ IU/mL

References:

1.Indian Thyroid Society guidelines for management of thyroid dysfunction during pregnancy. Clinical Practice Guidelines, New Delhi: Elsevier; 2012.

2. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, et al. Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum. Thyroid 2011;21:1081-25.

3. Dave A, Maru L, Tripathi M. Importance of Universal screening for thyroid disorders in first trimester of pregnancy. Indian J Endocr Metab [serial online] 2014 [cited 2014 Sep 25]; 18: 735-8. Available from: http://www.ijem.in/text.asp?2014/18/5/735/139221.

| *TOTAL PROTEIN [BLOOD] ALB:GLO RATIO , . | | | | | |
|--|-------------|--------------|-------|--|--|
| TOTAL PROTEIN (Method:BIURET METHOD) | <u>8.80</u> | 5.7-8.2 | g/dL | | |
| ALBUMIN (Method:BCG Dye Binding) | 4.4 | 3.2-4.8 g/dL | g/dL | | |
| GLOBULIN (Method:Calculated) | <u>4.40</u> | 1.8-3.2 | g/dl | | |
| AG Ratio (Method:Calculated) | 1.00 | 1.0 - 2.5 | | | |
| UREA,BLOOD (Method:Urease with GLDH) | 24.0 | 19 - 49 | mg/dL | | |

| UREA,BLOOD | 24.0 | 19 - 49 | mg/dL |
|---------------------------|------|---------|-------|
| (Method:Urease with GLDH) | | | |

| LIPID PROFILE, GEL SERUM | | | |
|--|-----------|--|-------|
| CHOLESTEROL-TOTAL (Method:CHOD – PAP) | 166 | Desirable: < 200 mg/dL Borderline high: 200-239 mg/dL High: > or =240 mg/dL | mg/dL |
| TRIGLYCERIDES (Method:ENZYMATIC (END POINT)) | 123 | Normal:: < 150, BorderlineHigh::150- 199, High:: 200-499, VeryHigh::>500 | mg/dL |
| HDL CHOLESTEROL (Method:ENZYMATIC (PEG)) | <u>39</u> | < 40 - Low 40-59- Optimum 60 - High | mg/dl |
| LDL CHOLESTEROL DIRECT (Method:HOMOGENOUS ENZYMATIC) | 99 | OPTIMAL: <100 mg/dL, Near optimal/ above optimal: 100-129 mg/dL, Borderline high: 130-159 mg/dL, High: 160-189 mg/dL, Very high: >=190 mg/dL | mg/dL |

KNK/26-03-2024/SR8911911 Page 3 of 12 Lab No.



Patient Name : PAYEL MONDAL : 25 Y 11 M 22 D Age : F

: Nadia, Krishnanagar - 741101 Lab Add.

: Dr.MEDICAL OFFICER

: 26/Mar/2024 10:45AM

: 26/Mar/2024 01:22PM Report Date

DEPARTMENT OF BIOCHEMISTRY

Ref Dr.

Collection Date

| Test Name | Result | Bio Ref. Interval | Unit | |
|--|--------|---|-------|--|
| VLDL (Method:Calculated) | 28 | < 40 mg/dl | mg/dL | |
| CHOL HDL Ratio (Method:Calculated) | 4.3 | LOW RISK 3.3-4.4 AVERA 4.47-7.1 MODERATE RISK HIGH RISK >11.0 | | |
| POTASSIUM,BLOOD (Method:ISE DIRECT) | 4.80 | 3.5 - 5.5 mEq/L | mEq/L | |

*** End Of Report ***

Gender

MD (Pathology) Consultant Pathologist Reg No. WBMC 64876



Patient Name : PAYEL MONDAL

Age : 25 Y 11 M 22 D

: F

Lab Add. : Nadia, Krishnanagar - 741101

: Dr.MEDICAL OFFICER : 26/Mar/2024 10:46AM

Report Date : 26/Mar/2024 02:00PM



DEPARTMENT OF HAEMATOLOGY

Ref Dr.

Collection Date

| Test Name Result | Bio Ref. Interval | Unit | |
|------------------|-------------------|------|--|
|------------------|-------------------|------|--|

*BLOOD GROUP ABO+RH [GEL METHOD], EDTA WHOLE BLOOD

ABO

(Method:Gel Card)

RH POSITIVE

(Method:Gel Card)

Gender

TECHNOLOGY USED: GEL METHOD

ADVANTAGES:

- Gel card allows simultaneous forward and reverse grouping.
- · Card is scanned and record is preserved for future reference.
- · Allows identification of Bombay blood group.
- Daily quality controls are run allowing accurate monitoring.

Historical records check not performed.

| *CBC WITH PLATELET (THROMBOCYTE) COUNT, EDTA WHOLE BLOOD | | | | | | |
|--|-------------|-----------------|----------|--|--|--|
| HEMOGLOBIN (Method:PHOTOMETRIC) | 12.1 | 12 - 15 | g/dL | | | |
| WBC (Method:DC detection method) | 8.8 | 4 - 10 | *10^3/µL | | | |
| RBC (Method:DC detection method) | 4.37 | 3.8 - 4.8 | *10^6/µL | | | |
| PLATELET (THROMBOCYTE) COUNT (Method:DC detection method/Microscopy) DIFFERENTIAL COUNT | 161 | 150 - 450*10^3 | *10^3/µL | | | |
| NEUTROPHILS (Method:Flowcytometry/Microscopy) | 56 | 40 - 80 % | % | | | |
| LYMPHOCYTES (Method:Flowcytometry/Microscopy) | 34 | 20 - 40 % | % | | | |
| MONOCYTES (Method:Flowcytometry/Microscopy) | 05 | 2 - 10 % | % | | | |
| EOSINOPHILS (Method:Flowcytometry/Microscopy) | 05 | 1 - 6 % | % | | | |
| BASOPHILS (Method:Flowcytometry/Microscopy) <u>CBC SUBGROUP</u> | 00 | 0-0.9% | % | | | |
| HEMATOCRIT / PCV (Method:Calculated) | 38.8 | 36 - 46 % | % | | | |
| MCV (Method:Calculated) | 88.9 | 83 - 101 fl | fl | | | |
| MCH (Method:Calculated) | 27.7 | 27 - 32 pg | pg | | | |
| MCHC (Method:Calculated) | <u>31.1</u> | 31.5-34.5 gm/dl | gm/dl | | | |
| RDW - RED CELL DISTRIBUTION WIDTH (Method:Calculated) | <u>15.7</u> | 11.6-14% | % | | | |
| PDW-PLATELET DISTRIBUTION WIDTH (Method:Calculated) | 41.1 | 8.3 - 25 fL | fL | | | |
| MPV-MEAN PLATELET VOLUME (Method:Calculated) | 14.8 | 7.5 - 11.5 fl | | | | |

*ESR (ERYTHROCYTE SEDIMENTATION RATE) , EDTA WHOLE BLOOD

1stHour <u>25</u> 0.00 - 20.00 mm/hr mm/hr

(Method:Westergren) **Lab No.** : KNK/26-03-2024/SR8911911 Page 5 of 12



Patient Name : PAYEL MONDAL

Age : 25 Y 11 M 22 D

:F

Lab Add. : Nadia, Krishnanagar - 741101

: Dr.MEDICAL OFFICER

Collection Date : 26/Mar/2024 10:46AM

Report Date : 26/Mar/2024 02:00PM

DEPARTMENT OF HAEMATOLOGY

Ref Dr.

| Test Name | Result | Bio Ref. Interval | Unit |
|-----------|--------|-------------------|------|
| | | | |

*** End Of Report ***

Gender

DR. SHABNAM PARVIN MD (Pathology) Consultant Pathologist Reg No. WBMC 64876

Lab No. : KNK/26-03-2024/SR8911911 Page 6 of 12



: PAYEL MONDAL Ref Dr. : Dr.MEDICAL OFFICER

Lab Add.

Age : 25 Y 11 M 22 D Collection Date :

Gender : F Report Date : 26/Mar/2024 12:46PM

DEPARTMENT OF X-RAY

X-RAY REPORT OF CHEST (PA) VIEW

FINDINGS:

Patient Name

Prominent bronchovascular marking noted over bilateral lung fields.

Both the hila are normal in size and position.

Mediastinum is in central position. Trachea is in midline.

Domes of diaphragm are smoothly outlined. Position is within normal limits.

Lateral costo-phrenic angles are clear.

The cardio-thoracic ratio is normal.

Bony thorax reveals no definite abnormality.

*** End Of Report ***

DR. VIMLESH JI VIMAL MBBS (Cal)

MBBS (Cal)
MD, DMRD(IPGME & R)
Consultant Radiologist
Reg No 61436

Page 7 of 12

Lab No. : KNK/26-03-2024/SR8911911



 Patient Name
 : PAYEL MONDAL
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 25 Y 11 M 22 D
 Collection Date
 : 26/Mar/2024 11:00AM

 Gender
 : F
 Report Date
 : 26/Mar/2024 07:47PM



DEPARTMENT OF CLINICAL PATHOLOGY

Test Name Result Bio Ref. Interval Unit

| *URINE ROUTINE ALL, ALL , URINE | | | |
|--|---------------|--------------|------|
| PHYSICAL EXAMINATION | | | |
| COLOUR | PALE YELLOW | | |
| APPEARANCE | SLIGHTLY HAZY | | |
| CHEMICAL EXAMINATION | | | |
| pH (Method:DIPSTICK) | 6.5 | 4.8 - 7.4 | |
| SPECIFIC GRAVITY (Method:DIPSTICK) | <u>1.010</u> | 1.016-1.022 | |
| PROTEIN (Method:DIPSTICK(Protein Error Principle)/MANUAL) | NOT DETECTED | NOT DETECTED | |
| GLUCOSE (Method:DIPSTICK (Glucose Oxidase - peroxidase)/ MANUAL) | NOT DETECTED | NOT DETECTED | |
| KETONES (ACETOACETIC ACID, ACETONE) | NOT DETECTED | NOT DETECTED | |
| (Method:Dipstick (Legals test)/Manual) BLOOD (Method:DIPSTICK(Pseudo Peroxidase Method)) | NEGATIVE | NOT DETECTED | |
| BILIRUBIN (Method:DIPSTICK(Azo-Diazo Reaction)/MANUAL) | ABSENT | NEGATIVE | |
| UROBILINOGEN (Method:DIPSTICK(Diazonium Ion Reaction)/MANUAL | NORMAL | NORMAL | |
| NITRITE (Method:DIPSTICK(GRIESS TEST)) | NEGATIVE | NEGATIVE | |
| LEUCOCYTE ESTERASE (Method:DIPSTICK) | NEGATIVE | NEGATIVE | |
| MICROSCOPIC EXAMINATION | | | |
| LEUKOCYTES (PUS CELLS) (Method:Microscopy) | 2 - 3 | 0-5 | /hpf |
| EPITHELIAL CELLS (Method:Microscopy) | 6 - 8 | 0-5 | /hpf |
| RED BLOOD CELLS (Method:Microscopy) | NOT DETECTED | 0-2 | /hpf |
| CAST (Method:Microscopy) | NOT DETECTED | NOT DETECTED | |
| CRYSTALS (Method:Microscopy) | NOT DETECTED | NOT DETECTED | |
| BACTERIA (Method:Microscopy) | NOT DETECTED | NOT DETECTED | |
| YEAST | NOT DETECTED | NOT DETECTED | |
| (Method:Microscopy) OTHERS | NIL | | |

Note:

- $1. \ All \ urine \ samples \ are \ checked \ for \ adequacy \ and \ suitability \ before \ examination.$
- 2. Analysis by urine analyzer of dipstick is based on reflectance photometry principle. Abnormal results of chemical examinations are confirmed by manual methods.
- 3. The first voided morning clean-catch midstream urine sample is the specimen of choice for chemical and microscopic analysis.
- 4. Negative nitrite test does not exclude urinary tract infections.
- 5. Trace proteinuria can be seen in many physiological conditions like exercise, pregnancy, prolonged recumbency etc.
- 6. False positive results for glucose, protein, nitrite, urobilinogen, bilirubin can occur due to use of certain drugs, therapeutic dyes, ascorbic acid, cleaning agents used in urine collection container.
- 7. Discrepancy between results of leukocyte esterase and blood obtained by chemical methods with corresponding pus cell and red blood cell count by microscopy can occur due to cell lysis.

Lab No. : KNK/26-03-2024/SR8911911 Page 8 of 12



 Patient Name
 : PAYEL MONDAL
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 25 Y 11 M 22 D
 Collection Date
 : 26/Mar/2024 11:00AM

 Gender
 : F
 Report Date
 : 26/Mar/2024 07:47PM



DEPARTMENT OF CLINICAL PATHOLOGY

Test Name Result Bio Ref. Interval Unit

8. Contamination from perineum and vaginal discharge should be avoided during collection, which may falsely elevate epithelial cell count and show presence of bacteria and/or yeast in the urine.

*** End Of Report ***

DR. SHABNAM PARVIN MD (Pathology) Consultant Pathologist Reg No. WBMC 64876

Lab No. : KNK/26-03-2024/SR8911911 Page 9 of 12



Patient Name : PAYEL MONDAL Ref Dr. : Dr.MEDICAL OFFICER

Age : 25 Y 11 M 22 D Collection Date

Gender : F Report Date : 26/Mar/2024 12:25PM



DEPARTMENT OF CARDIOLOGY

Lab Add.

| | DEPARTMENT OF CARDIOLOGY | | |
|--------------------|--------------------------|---------------------------|--|
| | | E.C.G. REPORT | |
| DATA HEART RATE | 84 Bpm | | |
| PR INTERVAL | 170 Ms | | |
| QRS DURATION | 76 Ms | | |
| QT INTERVAL | 326 Ms | | |
| QTC INTERVAL | 388 Ms | | |
| AXIS P WAVE | 54 Degree | | |
| QRS WAVE | 54 Degree | | |
| T WAVE | 34 Degree | | |
| IMPRESSION | Normal sinus rhyth | nm, within normal limits. | |

*** End Of Report ***

Dr. A C RAY
Department of Non-invasive
Cardiology

Lab No. : KNK/26-03-2024/SR8911911



Patient Name : PAYEL MONDAL Ref Dr. : Dr.MEDICAL OFFICER

Age : 25 Y 11 M 22 D Collection Date :

Gender : F Report Date : 26/Mar/2024 07:06PM



DEPARTMENT OF ULTRASONOGRAPHY

ULTRASONOGRAPHY OF WHOLE ABDOMEN

<u>LIVER</u>: Normal in shape and size but parenchymal echotexture early fatty changes. No focal lesion of altered echogenecity is seen. Intrahepatic biliary radicles are not dilated. The portal vein branches and hepatic veins are normal.

GALL BLADDER: Well distended lumen shows no intra-luminal calculus or mass. Wall thickness is normal. No pericholecystic collection or mass formation is noted.

PORTA HEPATIS: The portal vein (0.94 cm) is normal in caliber with clear lumen. The common bile duct (0.52 cm) is normal in caliber. Visualized lumen is clear.

PANCREAS: It is normal in shape, size and echopattern. Main pancreatic duct is not dilated. No focal lesion of altered echogenecity is seen. The peripancreatic region shows no abnormal fluid collection.

SPLEEN: It is normal in shape, size (8.64 cm) and shows homogeneous echopattern. No focal lesion is seen. No abnormal venous dilatation is seen in the splenic hilum.

<u>KIDNEYS</u>: Both Kidneys are normal in shape, size and position. Cortical echogenecity and thickness are normal with normal cortico-medullary differentiation in both kidneys. No calculus, hydronephrosis or mass is noted. The perinephric region shows no abnormal fluid collection.

Right Kidney measure: 9.51 cm, Left Kidney measure: 10.07 cm.

URETER: Both ureters are not dilated. No calculus is noted in either side.

URINARY BLADDER: It is adequately distended providing optimum scanning window. The lumen is clear and wall thickness is normal. Post void residual urine volume is insignificant.

<u>UTERUS</u>: It is mildly bulky in size (9.05 cm x 5.70 cm x 4.07 cm) but normal echopattern. Endometrial (thickness: 0.71 cm) and myometrial echotexture are within normal. No focal SOL is seen. Cervix is normal.

OVARIES: Both the ovaries are normal in shape, size and echopattern. No focal SOL is seen.

Right Ovary measures: 2.72 x 2.22 cm.

Left Ovary measures: 2.67 x 1.77 cm.

ADNEXA: No adnexal SOL is noted.

POD: No fluid is seen.

IMPRESSION:

- Early fatty changes in Liver.
- · Mild bulky Uterus.

Kindly note

Ø Ultrasound is not the modality of choice to rule out subtle bowel lesion.

Lab No. : KNK/26-03-2024/SR8911911 Page 11 of 12



Patient Name : PAYEL MONDAL Ref Dr. : Dr.MEDICAL OFFICER

Age : 25 Y 11 M 22 D Collection Date :

Gender : F Report Date : 26/Mar/2024 07:06PM



DEPARTMENT OF ULTRASONOGRAPHY

Lab Add.

Please Intimate us for any typing mistakes and send the report for correction within 7 days.

Ø The science of Radiological diagnosis is based on the interpretation of various shadows produced by both the normal and abnormal tissues and are not always conclusive. Further biochemical and radiological investigation & clinical correlation is required to enable the clinician to reach the final diagnosis.

The report and films are not valid for medico-legal purpose.

Patient Identity not verified.

Dr. Nishan Ghosh MBBS,CBET, FELLOW IN FOETAL ECHOCARDIOGRAPHY FGI,

Reg.NO: 67862


Lab No. : KNK/26-03-2024/SR8911911 Page 12 of 12

Patient report

Sample ID: D02132625093

Injection date 26/03/2024 01:29 PM Injection #: 17 D-10 Method: HbA1c

Rack #: --- Rack position: 7
Bio-Rad v: 5.00-2 S/N: #DM23E24805



Peak table - ID: D02132625093

| Peak | R.time | Height | Area | Area % |
|------------|--------|--------|---------|--------|
| A1a | 0.14 | 3168 | 10266 | 0.5 |
| Unknown | 0.22 | 3145 | 9758 | 0.5 |
| A1b | 0.29 | 5099 | 18670 | 0.9 |
| F | 0.52 | 1429 | 7183 | 0.4 |
| LA1c/CHb-1 | 0.65 | 4126 | 31917 | 1.6 |
| A1c | 0.86 | 8122 | 64476 | 4.5 |
| P3 | 1.30 | 26557 | 101938 | 5.1 |
| A0 | 1.40 | 695908 | 1762207 | 87.8 |

Total Area: 2006416

| Concentration: | % | mmol/mol |
|----------------|-----|----------|
| A1c | 4.5 | 26 |